217 related articles for article (PubMed ID: 18504090)
1. A double-blind, randomized, crossover comparison between single-dose and double-dose immediate-release oral morphine at bedtime in cancer patients.
Dale O; Piribauer M; Kaasa S; Moksnes K; Knobel H; Klepstad P
J Pain Symptom Manage; 2009 Jan; 37(1):68-76. PubMed ID: 18504090
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study.
Ridgway D; Sopata M; Burneckis A; Jespersen L; Andersen C
J Pain Symptom Manage; 2010 Apr; 39(4):712-20. PubMed ID: 20413058
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
4. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
Chang AK; Bijur PE; Baccelieri A; Gallagher EJ
Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer.
Currow DC; Plummer JL; Cooney NJ; Gorman D; Glare PA
J Pain Symptom Manage; 2007 Jul; 34(1):17-23. PubMed ID: 17601560
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
[TBL] [Abstract][Full Text] [Related]
8. Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial.
Israel FJ; Parker G; Charles M; Reymond L
J Pain Symptom Manage; 2010 Mar; 39(3):548-54. PubMed ID: 20083373
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain.
Beaulieu AD; Peloso P; Bensen W; Clark AJ; Watson CP; Gardner-Nix J; Thomson G; Piraino PS; Eisenhoffer J; Harsanyi Z; Darke AC
Clin Ther; 2007 Jan; 29(1):49-60. PubMed ID: 17379046
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled, cross-over pilot study to assess the effects of long-term opioid drug consumption and subsequent abstinence in chronic noncancer pain patients receiving controlled-release morphine.
Cowan DT; Wilson-Barnett J; Griffiths P; Vaughan DJ; Gondhia A; Allan LG
Pain Med; 2005; 6(2):113-21. PubMed ID: 15773875
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
Mercadante S; Villari P; Ferrera P; Porzio G; Aielli F; Verna L; Casuccio A
J Pain Symptom Manage; 2006 Aug; 32(2):175-9. PubMed ID: 16877185
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose.
Mercadante S; Villari P; Ferrera P; Bianchi M; Casuccio A
J Pain Symptom Manage; 2004 Apr; 27(4):352-9. PubMed ID: 15050663
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
[TBL] [Abstract][Full Text] [Related]
14. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery.
Oifa S; Sydoruk T; White I; Ekstein MP; Marouani N; Chazan S; Skornick Y; Weinbroum AA
Clin Ther; 2009 Mar; 31(3):527-41. PubMed ID: 19393843
[TBL] [Abstract][Full Text] [Related]
15. Normal-release oral morphine starting dose in cancer patients with pain.
Ripamonti CI; Campa T; Fagnoni E; Brunelli C; Luzzani M; Maltoni M; De Conno F;
Clin J Pain; 2009 Jun; 25(5):386-90. PubMed ID: 19454871
[TBL] [Abstract][Full Text] [Related]
16. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
17. Is there an ideal morphine dose for prehospital treatment of severe acute pain? A randomized, double-blind comparison of 2 doses.
Bounes V; Charpentier S; Houze-Cerfon CH; Bellard C; Ducassé JL
Am J Emerg Med; 2008 Feb; 26(2):148-54. PubMed ID: 18272093
[TBL] [Abstract][Full Text] [Related]
18. Control of severe pain with sustained-release morphine tablets v. oral morphine solution.
Arkinstall WW; Goughnour BR; White JA; Stewart JH
CMAJ; 1989 Mar; 140(6):653-7, 661. PubMed ID: 2645988
[TBL] [Abstract][Full Text] [Related]
19. Oral versus intravenous opioid dosing for the initial treatment of acute musculoskeletal pain in the emergency department.
Miner JR; Moore J; Gray RO; Skinner L; Biros MH
Acad Emerg Med; 2008 Dec; 15(12):1234-40. PubMed ID: 18945240
[TBL] [Abstract][Full Text] [Related]
20. Randomized double-blind placebo-controlled trial of two intravenous morphine dosages (0.10 mg/kg and 0.15 mg/kg) in emergency department patients with moderate to severe acute pain.
Birnbaum A; Esses D; Bijur PE; Holden L; Gallagher EJ
Ann Emerg Med; 2007 Apr; 49(4):445-53, 453.e1-2. PubMed ID: 16978739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
